

- CHMP – positive opinion
- Approval EMA

- In response to these questions, the EMA informed that they will be issuing today a timetable regarding the Opinion and Authorization procedure.
Will make sure to keep you posted.

- OMCL releases (or waiver requested?)

5.1.2a

- First shipments to national hubs (Netherlands) – what is the chance we will receive market authorized product in December this year?
- We will be providing delivery allocations based on the EU's allocation direction. Those initial deliveries will be provided to all contracted Member States.

- Any info with respect FMD-barcodes on packaging – Falsified Medicines Directive?
- We do have a 2D DataMatrix on our primary labels and our artwork does have anti-counterfeiting security features that we cannot disclose at this time.

Could we please receive your info (best case scenario) within 3 hours?

Provided info will be treated confidential.

We hope you can help us with this urgent request from our MoH.

Many thanks and best regards,

5.1.2e

5.1.2e | 5.1.2e | 5.1.2e

National Institute for Public Health and the Environment
Ministry of Health, Welfare and Sport
A. van Leeuwenhoeklaan 9 | 3721 MA Bilthoven
Postbus 1 | 3720 BA Bilthoven
The Netherlands

T: +31 | 5.1.2e
5.1.2e [@rivm.nl](mailto:5.1.2e@rivm.nl)
<http://www.rivm.nl>

From: 5.1.2e <5.1.2e@modernatx.com>
Sent: maandag 16 november 2020 15:17
To: 5.1.2e <5.1.2e@rivm.nl>; 5.1.2e <5.1.2e@rivm.nl>; 5.1.2e <5.1.2e@rivm.nl>; 5.1.2e <5.1.2e@rivm.nl>; 5.1.2e <5.1.2e@rivm.nl>

Cc: 5.1.2e <5.1.2e@moderntx.com>

Subject: Moderna Milestones: Phase III data interim analysis & shelf-life stability

Dear all,

I hope this finds you well.

On behalf of the whole Moderna team, I wanted to share a quick note to thank you for your time in speaking with us on November 2. We found our discussion interesting and valuable, and wanted to reaffirm that we are available to address any additional questions you may have over the coming weeks and months.

We also wanted to take this opportunity to share two key milestones with you: 1) the first interim analysis of our Phase III study, known as the COVE study, for our COVID-19 vaccine candidate mRNA-1273, and 2) an announcement on longer shelf-life. Both press releases are attached.

Please do not hesitate to reach out should you have any questions.

Best Wishes,

5.1.2e

5.1.2e

5.1.2e

5.1.2e

ModernaTX, Inc.

Mobile: +1 5.1.2e | moderntx.com

moderna

f t y in

 **Please consider the environment before printing this email**

Confidentiality notice and disclaimer: The information in this message and any attachments is intended for the exclusive use of the addressee(s), is confidential and may be privileged or otherwise protected from disclosure. Any review, retransmission, dissemination or other use of, or taking of any action in reliance upon, of any such information by persons or entities other than the intended addressee(s) is prohibited. If you have received this message in error and are not the intended addressee, please notify the sender immediately and delete this message and any attachments from your system without reading or disclosing them. If you are not the intended addressee, be advised that any use of the information in this message and any attachment is prohibited and may be unlawful, and you must not copy this message or attachment or disclose the contents to any other person.

Dit bericht kan informatie bevatten die niet voor u is bestemd. Indien u niet de geadresseerde bent of dit bericht abusievelijk aan u is verzonden, wordt u verzocht dat aan de afzender te melden en het bericht te verwijderen. Het RIVM aanvaardt geen aansprakelijkheid voor schade, van welke aard ook, die verband houdt met risico's verbonden aan het elektronisch verzenden van berichten.
www.rivm.nl De zorg voor morgen begint vandaag

This message may contain information that is not intended for you. If you are not the addressee or if this message was sent to you by mistake, you are requested to inform the sender and delete the message. RIVM accepts no liability for damage of any kind resulting from the risks inherent in the electronic transmission of messages.
www.rivm.nl/en Committed to health and sustainability

Dit bericht kan informatie bevatten die niet voor u is bestemd. Indien u niet de geadresseerde bent of dit bericht abusievelijk aan u is verzonden, wordt u verzocht dat aan de afzender te melden en het bericht te verwijderen. Het RIVM aanvaardt geen aansprakelijkheid voor schade, van welke aard ook, die verband houdt met risico's verbonden aan het elektronisch verzenden van berichten.
www.rivm.nl De zorg voor morgen begint vandaag

This message may contain information that is not intended for you. If you are not the addressee or if this message was sent to you by mistake, you are

requested to inform the sender and delete the message. RIVM accepts no liability for damage of any kind resulting from the risks inherent in the electronic transmission of messages.
www.rivm.nl/en Committed to *health and sustainability*